Compare CERT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERT | NVCR |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2020 | 2015 |
| Metric | CERT | NVCR |
|---|---|---|
| Price | $11.84 | $11.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $12.68 | ★ $26.14 |
| AVG Volume (30 Days) | ★ 2.6M | 1.8M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | $418,838,000.00 | ★ $655,353,000.00 |
| Revenue This Year | N/A | $12.95 |
| Revenue Next Year | $3.64 | $9.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.75 | 8.28 |
| 52 Week Low | $4.45 | $9.82 |
| 52 Week High | $12.61 | $21.45 |
| Indicator | CERT | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 65.90 | 31.84 |
| Support Level | $6.26 | $10.14 |
| Resistance Level | $12.61 | $18.43 |
| Average True Range (ATR) | 0.65 | 0.83 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 68.74 | 3.36 |
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.